ahlam1399
08-21-2015, 11:10 AM
**vartis buys remaining rights to GSK treatment in deal up to $1 billion
ZURICH (Reuters) - Swiss drugmaker **vartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's GlaxoSmithKline.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/492a6adf/sc/7/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=KOS7lVJHSlM:cFR37ZK2R3g:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=KOS7lVJHSlM:cFR37ZK2R3g:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=KOS7lVJHSlM:cFR37ZK2R3g:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=KOS7lVJHSlM:cFR37ZK2R3g:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=KOS7lVJHSlM:cFR37ZK2R3g:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/KOS7lVJHSlM
ZURICH (Reuters) - Swiss drugmaker **vartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's GlaxoSmithKline.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/492a6adf/sc/7/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=KOS7lVJHSlM:cFR37ZK2R3g:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=KOS7lVJHSlM:cFR37ZK2R3g:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=KOS7lVJHSlM:cFR37ZK2R3g:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=KOS7lVJHSlM:cFR37ZK2R3g:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=KOS7lVJHSlM:cFR37ZK2R3g:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/KOS7lVJHSlM